Takeda Pharmaceutical (TAK) Inventory (2017 - 2026)

Takeda Pharmaceutical has reported Inventory for 10 years, with the latest figure at $9.1 billion in Q2 2026.

• On a quarterly basis, Inventory rose 5.9% year-over-year to $9.1 billion in Q2 2026; TTM through Jun 2026 was $9.1 billion, a 5.9% increase from a year earlier, with the FY2026 full-year figure at $8.9 billion, up 11.44% from the prior year.
• Inventory was $9.1 billion for Q2 2026 at Takeda Pharmaceutical, up from $8.9 billion in the prior quarter.
• The five-year high for Inventory was $9.1 billion in Q4 2025, with the low at $6.6 billion in Q4 2022.
• Average Inventory over 5 years is $8.0 billion, with a median of $8.0 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Inventory dropped 8.04% in 2022, then advanced 20.56% in 2023.
• Over 5 years, Inventory stood at $6.6 billion in 2022, then rose by 20.56% to $7.9 billion in 2023, then advanced by 3.61% to $8.2 billion in 2024, then gained by 11.53% to $9.1 billion in 2025, then declined by 0.7% to $9.1 billion in 2026.
• The last three Inventory figures came in at $9.1 billion (Q2 2026), $8.9 billion (Q1 2026), and $9.1 billion (Q4 2025), per Business Quant data.